The state of patient-reported outcomes in atrial fibrillation: A review of current measures

PharmacoEconomics

Volumn 23, Issue 7, 2005, Pages 687-708

  Coyne, Karin ^a   Margolis, Mary Kay ^a   Grandy, Susan ^b   Zimetbaum, Peter ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; FLECAINIDE; WARFARIN;

ARTIFICIAL HEART PACEMAKER; CLINICAL TRIAL; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DEFIBRILLATOR; DISEASE SEVERITY; HEALTH CARE COST; HEALTH STATUS; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HUMAN; INTERMETHOD COMPARISON; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; INTERVIEW; LIFE SATISFACTION; MEDICAL LITERATURE; METHODOLOGY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RACE DIFFERENCE; RADIOFREQUENCY ABLATION; RATING SCALE; REVIEW; SCORING SYSTEM; SELF REPORT; SEX DIFFERENCE; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOM; TREATMENT OUTCOME; UNITED STATES;

ATRIAL FIBRILLATION; CLINICAL TRIALS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PARTICIPATION; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 22444448299     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523070-00004     Document Type: Review

References (69)

1. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003; 6: 522-31
2. Leidy NK, Rich M, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2 (2): 113-27
3. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155 (5):469-73
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18): 2370-5
5. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104 (17): 2118-50
6. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41 (10): 1690-6
7. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36 (4): 1303-9
8. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356 (9244): 1789-94
9. Moeremans K, Aliot E, de Chillou C, et al. Second line pharmacological management of paroxysmal and persistant atrial fibrillation in France: a cost analysis. Value Health 2000; 3: 407-16
10. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158 (3): 229-34
11. Ware JE, Snow KK, Kosinski MK, et al. SF-36 Health Survey: Manual and Interpretation Guide. Boston (MA): The Health Institute, New England Medical Center, 1993
12. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am Heart J 1992; 124 (2): 381-6
13. Deaton C, Dunbar SB, Moloney M, et al. Patient experiences with atrial fibrillation and treatment with implantable atrial defibrillation therapy. Heart Lung 2003; 32 (5): 291-9
14. Ganiats TG, Palinkas LA, Kaplan RM. Comparison of Quality of Well-Being scale and Functional Status Index in patients with atrial fibrillation. Med Care 1992; 30 (10): 958-64
15. Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation. New York Heart Association. Am Heart J 1998; 135 (5 Pt 1): 819-24
16. Gehring J, Perz S, Stieber J, et al. Cardiovascular risk factors, ECG abnormalities and quality of life in subjects with atrial fibrillation. Soz Praventivmed 1996; 41 (3): 185-93
17. Hamer ME, Blumenthal JA, McCarthy EA, et al. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 1994; 74 (8): 826-9
18. Howes CJ, Reid MC, Brandt C, et al. Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation. J Cardiovasc Pharmacol Ther 2001; 6 (1): 23-9
19. Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 2000; 86 (7): 764-8
20. Savelieva I, Paquette M, Dorian P, et al. Quality of life in patients with silent atrial fibrillation. Heart 2001; 85 (2): 216-7
21. van den Berg MP, Hassink RJ, Tuinenburg AE, et al. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J 2001; 22 (3): 247-53
22. Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997; 79 (2): 145-9
23. Gronefeld GC, Lilienthal J, Kuck KH, et al. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 2003; 24 (15): 1430-6
24. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2004; 43 (2): 241-7
25. Hohnloser SH, Kuck KH, Lilienthal J, et al. Rate and rhythm control showed similar symptom improvement in atrial fibrillation. ACP J Club 2001; 135: 14
26. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347 (23): 1825-33
27. Berry C, Stewart S, Payne EM, et al. Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice. Int J Cardiol 2001; 81 (1): 29-35
28. Brignole M, Menozzi C, Gasparini M, et al. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002; 23 (11): 892-900
29. Channer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004; 25 (2): 144-50
30. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002; 143 (6): 984-90
31. Fung JW, Chan SK, Yeung LY, et al. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Eur J Heart Fail 2002; 4 (4): 489-94
32. Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol 2001; 28 (5-6): 446-50
33. Anselme F, Saoudi N, Poty H, et al. Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. Circulation 1999; 99 (4): 534-40
34. Brignole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994; 74 (3): 242-6
35. Brignole M, Gianfranchi L, Menozzi C, et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 1997; 96 (8): 2617-24
36. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998; 98 (10): 953-60
37. Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996; 94 (7): 1585-91
38. Duff HJ, Raj SR, Exner DV, et al. Randomized controlled trial of fixed rate versus rate responsive pacing after radiofrequency atrioventricular junction ablation: quality of life, ventricular refractoriness, and paced QT dispersion. J Cardiovasc Electrophysiol 2003; 14 (11): 1163-70
39. Erdogan A, Carlsson J, Neumann T, et al. Quality-of-life in patients with paroxysmal atrial fibrillation after catheter ablation: results of long-term follow-up. Pacing Clin Electrophysiol 2003; 26 (3): 678-84
40. Fitzpatrick AP, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131 (3): 499-507
41. Goldberg A, Menen M, Mickelsen S, et al. Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources. J Interv Card Electrophysiol 2003; 8 (1): 59-64
42. Jensen SM, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1995; 18 (9 Pt 1): 1609-14
43. Jessurun ER, van Hemel NM, Defauw JJ, et al. A randomized study of combining maze surgery for atrial fibrillation with mitral valve surgery. J Cardiovasc Surg (Torino) 2003; 44 (1): 9-18
44. Kay GN, Bubien RS, Epstein AE, et al. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988; 62 (10 Pt 1): 741-4
45. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol 1998; 2 (2): 121-35
46. Larson MS, McDonald K, Young C, et al. Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia. Am J Cardiol 1999; 84 (4): 471-3, A9
47. Lee SH, Chen SA, Tai CT, et al. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol 1998; 31 (3): 637-44
48. Lee SH, Tai CT, Yu WC, et al. Effects of radiofrequency catheter ablation on quality of life in patients with atrial flutter. Am J Cardiol 1999; 84 (3): 278-83
49. Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002; 39 (8): 1258-63
50. Levy T, Walker S, Mason M, et al. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study. Heart 2001; 85 (2): 171-8
51. Levy T, Walker S, Rex S, et al. No incremental benefit of multisite atrial pacing compared with right atrial pacing in patients with drug refractory paroxysmal atrial fibrillation. Heart 2001; 85 (1): 48-52
52. Lonnerholm S, Blomstrom P, Nilsson L, et al. Effects of the maze operation on health-related quality of life in patients with atrial fibrillation. Circulation 2000; 101 (22): 2607-11
53. Manolis AG, Katsivas AG, Lazaris EE, et al. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 1998; 2 (1): 71-6
54. Marshall HJ, Harris ZI, Griffith MJ, et al. Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: effective treatment for drug refractory paroxysmal atrial fibrillation. Heart 1998; 79 (6): 543-7
55. Natale A, Zimerman L, Tomassoni G, et al. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol 1996; 78 (12): 1431-3
56. Natale A, Zimerman L, Tomassoni G, et al. AV node ablation and pacemaker implantation after withdrawal of effective rate-control medications for chronic atrial fibrillation: effect on quality of life and exercise performance. Pacing Clin Electrophysiol 1999; 22 (11): 1634-9
57. Newman DM, Dorian P, Paquette M, et al. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J 2003; 145 (5): 841-6
58. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled non-randomized long-term study. J Am Coll Cardiol 2003; 42 (2): 185-97
59. Simpson CS, Yee R, Lee JK, et al. Safety and feasibility of a novel rate-smoothed ventricular pacing algorithm for atrial fibrillation. Am Heart J 2001; 142 (2): 294-300
60. Spurrell P, Mitchell A, Kamalvand K, et al. Quality of life after use of the patient activated atrial defibrillator. Int J Clin Pract 2003; 57 (1): 30-4
61. Stambler BS, Ellenbogen K, Zhang X, et al. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14 (11): 1180-6
62. Tada H, Naito S, Kurosaki K, et al. Segmental pulmonary vein isolation for paroxysmal atrial fibrillation improves quality of life and clinical outcomes. Circ J 2003; 67 (10): 861-5
63. Twidale N, Manda V, Nave K, et al. Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Am Heart J 1998; 136 (4 Pt 1): 647-57
64. Twidale N, McDonald T, Nave K, et al. Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation. Pacing Clin Electrophysiol 1998; 21 (4 Pt 1): 641-51
65. Weerasooriya R, Davis M, Powell A, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003; 41 (10): 1697-702
66. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management: the AFFIRM study design. Am J Cardiol 1997; 79 (9): 1198-202
67. Fitts SM, Hill MR, Mehra R, et al. Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. DAPPAF Phase 1 Investigators. J Interv Card Electrophysiol 1998; 2 (2): 139-44
68. Roy D, Talajic M, Thibault B, et al. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Am J Cardiol 1997; 80 (4): 464-8
69. Engelmann MD, Pehrson S. Quality of life in nonpharmacologic treatment of atrial fibrillation. Eur Heart J 2003; 24 (15): 1387-400